222 related articles for article (PubMed ID: 33892656)
1. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
Yao H; Chen X; Tan X
BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
[TBL] [Abstract][Full Text] [Related]
2. Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy.
Liao Z; Li T; Zhang C; Liu X; Xing R; Teng S; Yang Y; Zhao G; Bai X; Zhao J; Yang J
Cancer Biol Med; 2020 May; 17(2):501-512. PubMed ID: 32587785
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: An observational study.
Zhu B; Li J; Xie Q; Diao L; Gai L; Yang W
Cancer Biol Ther; 2018 Mar; 19(3):198-204. PubMed ID: 29261005
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis.
Liu JY; Zhu BR; Wang YD; Sun X
Int J Clin Oncol; 2020 Jun; 25(6):1195-1205. PubMed ID: 32215805
[TBL] [Abstract][Full Text] [Related]
6. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
Xia X; Jiang W; Qi W; Hong B; Zhao W
Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.
Zheng K; Xu M; Wang L; Yu X
Medicine (Baltimore); 2018 Aug; 97(31):e11734. PubMed ID: 30075583
[TBL] [Abstract][Full Text] [Related]
8. [Clinical efficacy and safety of apatinib combined with chemotherapy for osteosarcoma and soft tissue sarcoma with pulmonary metastasis].
Li SL; Yang QK; Chen P; Zheng K; Wang W; Pei Y; Zhang XJ
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):309-314. PubMed ID: 31014058
[No Abstract] [Full Text] [Related]
9. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.
Xie L; Xu J; Sun X; Guo W; Gu J; Liu K; Zheng B; Ren T; Huang Y; Tang X; Yan T; Yang R; Sun K; Shen D; Li Y
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376724
[TBL] [Abstract][Full Text] [Related]
10. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
[TBL] [Abstract][Full Text] [Related]
12. [Clinical study of apatinib combined with chemotherapy for advanced non-small cell lung cancer with negative driving genes].
Li YF; Jiang HY; Li Q; Zhu M; Lyu J; Zhao HY
Zhonghua Zhong Liu Za Zhi; 2019 Oct; 41(10):775-781. PubMed ID: 31648501
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non-small cell lung cancer: A meta-analysis.
Li Z; Liu Z; Wu Y; Li H; Sun Z; Han C; Zhang X; Zhang J
Thorac Cancer; 2021 Nov; 12(21):2838-2848. PubMed ID: 34622571
[TBL] [Abstract][Full Text] [Related]
14. The safety of apatinib for the treatment of gastric cancer.
Geng R; Song L; Li J; Zhao L
Expert Opin Drug Saf; 2018 Nov; 17(11):1145-1150. PubMed ID: 30324820
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.
Tian Z; Gu Z; Wang X; Liu Z; Yao W; Wang J; Zhang P; Cai Q; Ge H
Medicine (Baltimore); 2019 May; 98(19):e15650. PubMed ID: 31083265
[TBL] [Abstract][Full Text] [Related]
17. Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China.
Xie L; Guo W; Wang Y; Yan T; Ji T; Xu J
BMC Cancer; 2018 Apr; 18(1):396. PubMed ID: 29625604
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Efficiency and Safety of Apatinib in Advanced Bone and Soft Tissue Sarcomas: A Systematic Review and Meta-Analysis.
Long Z; Huang M; Liu K; Li M; Li J; Zhang H; Wang Z; Lu Y
Front Oncol; 2021; 11():662318. PubMed ID: 33816318
[TBL] [Abstract][Full Text] [Related]
19. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
20. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
Liu G; Wang C; He Y; E M
BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]